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ABSTRACT
Introduction: Little is known regarding age-
related risk of nephrotoxicity during
vancomycin therapy after the publication of
the 2009 vancomycin consensus guidelines for
therapeutic drug monitoring. We sought to
evaluate incidence and risk factors for acute
kidney injury in three age groups.
Methods: Matched cohort study of patients
receiving vancomycin, grouped by age: young
adults (18–64 years), older adults (65–79 years)
and very elderly (C80 years), matched on
previously published risk factors for
nephrotoxicity. Outcomes included traditional
vancomycin nephrotoxicity and Acute Kidney
Injury Network-modified definition of
nephrotoxicity.
Results: The incidence of acute kidney injury
was 34.1% vs. 34.1% vs. 31.8% in the young,
older adults and very elderly groups,
respectively (p = 0.97). In the logistic
regression model, after adjusting for baseline
risk factors, age was not a significant predictor
of acute kidney injury. Lower respiratory tract
infection (adjusted odds ratio [aOR] 5.18; 95%
confidence interval [CI] 2.15–12.41) and
duration of treatment (aOR 1.12; 95% CI
1.03–1.22) were found to be independently
associated with outcome.
Conclusion: No differences in risk of acute
kidney injury were identified between young,
older, and very elderly adults when adjusting
for other risk factors. Further research is
required to identify strategies to optimize the
safety of vancomycin in the aging population.
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INTRODUCTION
Vancomycin has long been the workhorse agent
for management of infections due to
methicillin-resistant Staphylococcus aureus
(MRSA); however, its clinical use is limited by
nephrotoxicity [1–10]. While older data
suggested that nephrotoxicity was initially
associated with impurities in original
formulations [1, 11], newer data suggest that
nephrotoxicity is associated with risk factors,
including patient-specific risk factors [8, 9],
concurrent nephrotoxins [5–7, 10] and greater
vancomycin exposures [2, 3]. Risk factor
identification has greatly improved the ability
of clinicians to determine which patients are at
high risk for nephrotoxicity.
Despite improvements in the literature and
practice, there are still limited data on renal
safety of vancomycin in the very elderly
(age C 80 years old). In 2002, the United
Nations deemed the very elderly to be the
fastest growing age group worldwide [12]. As
of 2010, in the United States, when a person
survives up to age 80, they are expected to live
an additional 9.1 years [13]. This increased time
at risk for infectious diseases, coupled with an
increased prevalence of MRSA infections [14],
establishes a great need for information on the
safety of vancomycin in these patients.
Previous investigations have provided
valuable insight into age-related differences in
risk of nephrotoxicity with vancomycin use.
Twenty years ago, Vance-Bryan et al. [7]
conducted a retrospective cohort study
examining the comparative incidence of
nephrotoxicity in the elderly (age C 60 years)
and young (age\60 years). This study observed
an increase in nephrotoxicity in the elderly
population; however, this difference was
thought to be due to an unequal distribution
of other risk factors, like use of loop diuretics
[7]. Since then, routine targets for vancomycin
serum trough concentrations have changed,
with recommendations of troughs greater than
10 mg/L for all patients, and 15–20 mg/L for
specific indications [15]. The most recent data
observing vancomycin nephrotoxicity have
linked elevated serum trough concentrations
and nephrotoxicity [3, 5, 9]; some of the studies
have adjusted for age, however, none have been
designed a priori to compare nephrotoxicity
across age groups. The present study was
conducted to estimate the relative risk of
nephrotoxicity in very elderly adults receiving
vancomycin as compared to older (65–79 years)
and younger adults (\65 years) while




This was an institutional review board-
approved, retrospective, matched cohort study
at an urban, tertiary care teaching hospital
serving a wide variety of medical and surgical
specialties. All procedures followed were in
accordance with the ethical standards of the
responsible committee on human
experimentation (institutional and national)
and with the Helsinki Declaration of 1975, as
revised in 2000. Informed consent was waived
by the institutional review board.
Patients receiving intravenous (IV)
vancomycin between January 2011 and April
2013 were screened. Patients included were
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aged at least 18 years, received at least four
consecutive vancomycin doses, and had at least
one recorded vancomycin serum trough
concentration during the course of therapy.
Patients were excluded if they had concurrent
acute kidney injury prior to initiation of
vancomycin (defined as an increase in serum
creatinine of 0.3 mg/dL or 50% within 48 h
prior to starting vancomycin, or if urine output
was \0.5 mL/kg/h for at least 6 h immediately
before the initiation of vancomycin), were
pregnant, or had an absolute neutrophil count
\1,000 cells/mm3.
Patients were categorized by age as young
(18–64 years), older adults (65–79 years) and
very elderly (C80 years). Consecutive very
elderly patients were matched 1:1:1 with
consecutive young and older adult patients on
the basis of four classes of risk factors for
nephrotoxicity: (1) history of acute kidney
injury [8] or pre-existing chronic renal disease
(as noted by baseline serum creatinine
C1.30 mg/dL), (2) weight C110 kg or receipt of
high-dose IV vancomycin (at least 4 g per day)
[2], (3) concurrent receipt of nephrotoxins (e.g.,
acyclovir, IV aminoglycosides, IV amphotericin
B, IV contrast dye, loop diuretics, IV colistin) [1,
6, 16] with IV vancomycin, and (4) concurrent
receipt of IV vasopressors (norepinephrine,
phenylephrine, or dopamine) with IV
vancomycin. Vancomycin was dosed as an
intermittent infusion by clinical pharmacists
in accordance with the 2009 consensus
guidelines for vancomycin therapeutic drug
monitoring [15]. The primary outcome of
interest was nephrotoxicity, defined as an
abrupt (within 48 h) increase in serum
creatinine of 0.5 mg/dL or 50% above baseline
for at least two consecutive measurements [15].
Secondary outcomes included Acute Kidney
Injury Network (AKIN)-modified definition of
nephrotoxicity [8], defined as an increase in
serum creatinine of 0.3 mg/dL, a decrease in
creatinine clearance of at least 50% or a decrease
in urine output to\0.5 mL/kg/h for at least 6 h.
Data Analysis
Descriptive statistics were used to characterize
the cohort with respect to patient
demographics, treatment characteristics and
outcomes. Categorical data were described as
proportions, and continuous data were
described as means and standard deviations or
medians an interquartile ranges, as appropriate.
Outcomes and patient characteristics were
compared between age groups.
Odds ratios were calculated for odds of
nephrotoxicity and acute kidney injury for
each age group with the young group as a
reference category. Categorical data were
analyzed using Chi-square test. Continuous
parametric data were analyzed using one-way
analysis of variance. Continuous non-
parametric data were analyzed via one-way
Kruskal–Wallis analysis of variance test, where
appropriate. Lastly, a multivariable logistic
regression model was constructed to determine
the association between the age group and
nephrotoxicity and acute kidney injury. Age
was entered into the model and any variables
found to have an association with the outcome
of interest (p\0.20) or that had clinical
rationale were considered for the multivariable
logistic regression model using backward-
stepwise regression. All analyses were
conducted using SPSS software, version 21.0
(SSPS Inc., Chicago, IL, USA).
Sample size assumption was based on the risk
of nephrotoxicity in previously published
studies [2], with a 7-day median duration of
therapy, maximum risk (approximately 35%) in
the very elderly and minimal risk
(approximately 10%) in the young group. In
Infect Dis Ther (2013) 2:201–208 203
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order to detect a difference at a 0.05 level of
significance and with 80% power,
approximately 40 patients were needed in
each age group.
RESULTS
Data were obtained for 132 patients meeting
inclusion criteria. There were 44 patients in
each stratum. Baseline characteristics (Table 1)
were similar between groups, with limited
exceptions other than age-related differences.
The most common indications for vancomycin
treatment were lower respiratory tract,
bloodstream and skin and soft tissue
infections. All patients had vancomycin
trough concentrations obtained at steady state:
in the respective young, older adults and very
elderly groups, 75.0%, 77.3% and 77.3% of
patients had an initial concentration greater
than 10 mg/L, and 47.7%, 45.5% and 31.8% of
patients had a 15 mg/L or greater
concentration. The two most common
baseline risk factors for nephrotoxicity were
history of acute kidney injury or chronic kidney
disease (36.4%) and concurrent receipt of
nephrotoxins (36.4%). Duration of treatment
was significantly longer in the elderly group vs.
all other groups (9 vs. 7 days, respectively;
p = 0.02).
There were seven episodes of nephrotoxicity
and 44 episodes of acute kidney injury within
the cohort. The incidence of nephrotoxicity was
2.3%, 9.1% and 4.5% in the young, older adult
and very elderly groups, respectively (p = 0.35,
Fig. 1). The incidence of acute kidney injury was
34.1%, 34.1% and 31.8% in the young, older
adults and very elderly groups, respectively
(p = 0.97, Fig. 1). Relevant predictors for acute
kidney injury, including all variables with
p\0.2 in bivariate comparison, are listed in
Table 2. Since there were only seven episodes of
nephrotoxicity, only acute kidney injury was
explored in the multivariable analysis.
In the logistic regression model, age was
entered into the model using the young group
as the reference. Based on the pre-specified
criteria for model entry and removal, age,
lower respiratory tract infection, length of
therapy and presence of at least two different
risk factors at baseline were included in the final
model. Age was not identified as a significant
predictor. Adjusting for the presence of more
than one baseline risk factor, both lower
respiratory tract infection and longer duration
of therapy were significant predictors for acute
kidney injury.
DISCUSSION
In the era of the 2009 consensus vancomycin
guidelines, no independent association between
acute kidney injury and advanced age was
found in this matched cohort. These findings
are similar to work predating these consensus
recommendations [7]. Therefore, clinicians
should not routinely use age alone to assess
the risk of nephrotoxicity in patients receiving
vancomycin. Factors that were found to be
associated with acute kidney injury in our
study included lower respiratory tract infection
and longer duration of therapy, which are also
consistent with more recent observational
studies [3, 9]. Importantly, the multivariable
analysis of this study was based on the
secondary endpoint of AKIN-defined
nephrotoxicity. The AKIN method of
identifying nephrotoxicity has been shown to
be more sensitive than the traditional definition
of nephrotoxicity [15], and also explains the
higher incidence of acute kidney injury
identified in this cohort.
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There are several potential explanations for
the finding that lower respiratory tract infection
was associated with nephrotoxicity. Recent
guidelines recommend that due to poor lung
penetration of vancomycin [17], a target trough
of 15–20 mg/L is utilized for these infections
[15, 18, 19]. This target trough has also been
associated with increased incidence of
nephrotoxicity [3, 5, 6, 9]. In the present
study, targeting a trough concentration of
15–20 mg/L was associated with
nephrotoxicity in bivariate analysis; because of








Age (years) 52 (41–59) 70 (66–75) 87 (82–90) \0.01
Male sex 21 (48) 19 (43) 20 (46) 0.91
Baseline SCr (mg/dL) 0.86 (0.67–1.2) 1.00 (0.71–1.24) 1.07 (0.96–1.36) 0.01
CrCl (mL/min) 73 (54–92) 45 (37–60) 34 (26–45) \0.01
Charlson score 1 (0–3) 2 (1–3) 2 (1–3) 0.11
Race
Caucasian 18 (40.9) 11 (25.0) 19 (43.2) 0.11
African American 21 (47.7) 21 (47.7) 22 (50.0)
Hispanic 1 (2.3) 0 (0.0) 0 (0.0)
Asian 1 (2.3) 4 (9.1) 0 (0.0)
Other 3 (6.8) 8 (18.2) 3 (6.8)
Infection sitea
Abdominal 1 (2.3) 3 (6.8) 0 (0.0) 0.16
Blood 11 (25.0) 9 (20.5) 13 (29.5) 0.61
Bone 3 (6.8) 1 (2.3) 1 (2.3) 0.44
Central nervous system 3 (6.8) 0 (0.0) 4 (9.1) 0.14
Genitourinary 2 (4.5) 7 (15.9) 8 (18.2) 0.12
Joint 0 (0) 0 (0) 1 (2.3) 0.36
Lower respiratory tract 13 (29.5) 19 (43.2) 17 (38.6) 0.40
Skin and soft tissue 9 (20.5) 5 (11.4) 5 (11.4) 0.37
Wound 2 (4.5) 0 (0) 0 (0) 0.13
Other 3 (6.8) 2 (4.5) 1 (2.3) 0.59
Goal vancomycin trough 15–20 mg/L 31 (70.5) 30 (68.2) 34 (77.3) 0.61
Length of treatment (days) 7 (5–9) 9 (6–12) 7 (5–10) 0.05
Risk factors for nephrotoxicity
History of AKI or chronic kidney disease 16 (36.4) 16 (36.4) 16 (36.4) 1.00
High-dose vancomycinb or weight C110 kg 1 (2.3) 1 (2.3) 1 (2.3) 1.00
Vasopressors 2 (4.5) 2 (4.5) 2 (4.5) 1.00
Nephrotoxinsc 16 (36.4) 16 (36.4) 1 (36.4) 1.00
Data are median (interquartile range) or n (%)
AKI acute kidney injury, CrCl creatinine clearance, SCr serum creatinine
a Infection sites are not mutually exclusive
b At least 4 g of vancomycin per day
c Acyclovir, IV aminoglycosides, IV amphotericin B, IV contrast dye, loop diuretics, IV colistin
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covariance with lower respiratory tract
infections, the stronger bivariate predictor was
used in the multivariate model. In addition, the
associated pathology of sepsis in patients with
lower respiratory tract infections may increase
the risk of acute kidney injury. Sepsis has been
shown in experimental models to increase the
risk of acute kidney injury [20]; however, septic
shock, as evidenced by use of vasopressors, was
not common in this cohort.
This study is not without limitations. As with
any retrospective study, causality cannot be
proven, and data are subject to observer biases
at the time of documentation. There is also the
possibility that measured and unmeasured
confounders influenced outcome. The
matched cohort design with multivariable
analysis may have reduced this effect. This is
the first matched study to specifically examine
the relationship between age and acute kidney
injury during vancomycin therapy. These data
must be considered carefully. Although a
Fig. 1 Incidence of nephrotoxicity in each age group. AKI
acute kidney injury, NT nephrotoxicity
Table 2 Bivariate and multivariate associations with acute kidney injury
Variable OR 95% CI p aOR 95% CI p
Age group
Young (reference) 1.00 N/A N/A 1.00 N/A N/A
Older adults 1.00 0.41–2.42 1.00 0.69 0.25–1.92 0.48
Very elderly 0.90 0.37–2.20 0.82 0.78 0.28–2.26 0.80
CrCl (mL/min) 0.98 0.96–1.00 0.05 – – –
Charlson score 1.30 1.05–1.61 0.02 – – –
Infection sitea
Blood 0.36 0.14–0.94 0.03 – – –
Genitourinary 0.38 0.11–1.43 0.14 – – –
Lower respiratory tract 4.08 1.90–8.78 \0.01 5.18 2.15–12.41 \0.01
Goal vancomycin trough 15–20 mg/L 2.21 0.91–5.36 0.07 – – –
Length of treatment (days) 1.08 1.00–1.16 0.04 1.12 1.03–1.22 \0.01
Risk factors for nephrotoxicity
Vasopressors 4.30 0.76–24.46 0.10 – – –
Nephrotoxins 2.06 0.98–4.35 0.06 – – –
C2 risk factors at baseline 7.00 2.08–23.55 \0.01 6.94 1.81–26.66 \0.01
aOR adjusted odds ratio, CI conﬁdence interval, CrCl creatinine clearance, OR odds ratio
a Infection sites are not mutually exclusive. Data are median (interquartile range) or n (%)
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matched cohort provides considerable evidence
that age alone is not a significant risk factor for
acute kidney injury during vancomycin
therapy, extrapolation of kidney injury
incidence within the general population is
more difficult. These data provide an
additional rationale for exercising caution
when using vancomycin in patients requiring
longer duration of therapy or with pre-existing
risk factors, regardless of age.
CONCLUSION
In this matched cohort study, there was no
difference detected in risk of nephrotoxicity or
acute kidney injury between young, older, and
very elderly adults receiving vancomycin in an
acute care inpatient facility. Further research is
required to identify strategies to optimize the
safety of vancomycin in the aging population.
ACKNOWLEDGMENTS
The authors wish to thank Henry Ford Hospital
Department of Pharmacy Services ID PRIME
members for editorial review of the manuscript.
No funding or sponsorship was received for this
study or publication of this article.
These findings were presented in part as
abstract at the 53rd ICAAC in Denver, CO,
USA on September 11, 2013.
Dr. Susan L. Davis is the guarantor for this
article, and takes responsibility for the integrity
of the work as a whole.
Conflict of interest. Joseph J. Carreno,
Anthony Jaworski and Rachel M. Kenney
declare no conflict of interest.
Susan L. Davis has served as a paid consultant
with Forest Inc., Durata, and Premier Inc.
Compliance with ethics guidelines. All
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000. Informed consent was waived by the
institutional review board.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution Noncommercial License which
permits any noncommercial use, distribution,
and reproduction in any medium, provided the
original author(s) and the source are credited.
REFERENCES
1. Farber BF, Moellering RC Jr. Retrospective study of
the toxicity of preparations of vancomycin from
1974 to 1981. Antimicrob Agents Chemother.
1983;23:138–41.
2. Lodise TP, Lomaestro B, Graves J, Drusano GL.
Larger vancomycin doses (at least four grams per
day) are associated with an increased incidence of
nephrotoxicity. Antimicrob Agents Chemother.
2008;52:1330–6.
3. Lodise TP, Patel N, Lomaestro BM, Rodvold KA,
Drusano GL. Relationship between initial
vancomycin concentration-time profile and
nephrotoxicity among hospitalized patients. Clin
Infect Dis. 2009;49:507–14.
4. Patel N, Pai MP, Rodvold KA, Lomaestro B, Drusano
GL, Lodise TP. Vancomycin: we can’t get there from
here. Clin Infect Dis. 2011;52:969–74.
5. Jeffres MN, Isakow W, Doherty JA, Micek ST, Kollef
MH. A retrospective analysis of possible renal
toxicity associated with vancomycin in patients
with health care-associated methicillin-resistant
Staphylococcus aureus pneumonia. Clin Ther.
2007;29:1107–15.
6. Cano EL, Haque NZ, Welch VL, et al. Incidence of
nephrotoxicity and association with vancomycin
use in intensive care unit patients with pneumonia:
retrospective analysis of the IMPACT-HAP
Database. Clin Ther. 2012;34:149–57.
Infect Dis Ther (2013) 2:201–208 207
123
7. Vance-Bryan K, Rotschafer JC, Gilliland SS, Rodvold
KA, Fitzgerald CM, Guay DR. A comparative
assessment of vancomycin-associated
nephrotoxicity in the young versus the elderly
hospitalized patient. J Antimicrob Chemother.
1994;33:811–21.
8. Minejima E, Choi J, Beringer P, Lou M, Tse E, Wong-
Beringer A. Applying new diagnostic criteria for
acute kidney injury to facilitate early identification
of nephrotoxicity in vancomycin-treated patients.
Antimicrob Agents Chemother. 2011;55:3278–83.
9. Bosso JA, Nappi J, Rudisill C, et al. Relationship
between vancomycin trough concentrations and
nephrotoxicity: a prospective multicenter trial.
Antimicrob Agents Chemother. 2011;55:5475–9.
10. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar
PH. Nephrotoxicity of vancomycin, alone and with
an aminoglycoside. J Antimicrob Chemother.
1990;25:679–87.
11. Levine DP. Vancomycin: a history. Clin Infect Dis.
2006;42(Suppl 1):S5–12.
12. United Nations. World Population Ageing:
1950–2050 Executive Summary [Webpage].
Internet: United Nations; 2002. Available from:
http://www.un.org/esa/population/publications/
worldageing19502050/pdf/62executivesummary_
english.pdf. Accessed 10 June 2013.
13. Murphy SL, Xu J, Kochanek KD. Deaths: final data
for 2010. Natl Vital Statist Rep. 2013;61:1–55.
14. Klein E, Smith DL, Laxminarayan R.
Hospitalizations and deaths caused by methicillin-
resistant Staphylococcus aureus, United States,
1999–2005. Emerg Infect Dis. 2007;13:1840–6.
15. Rybak MJ, Lomaestro BM, Rotschafer JC, et al.
Vancomycin therapeutic guidelines: a summary of
consensus recommendations from the infectious
diseases Society of America, the American Society of
Health-System Pharmacists, and the Society of
Infectious Diseases Pharmacists. Clin Infect Dis.
2009;49:325–7.
16. Pauly DJ, Musa DM, Lestico MR, Lindstrom MJ,




17. Lodise TP, Drusano GL, Butterfield JM, Scoville J,
Gotfried M, Rodvold KA. Penetration of
vancomycin into epithelial lining fluid in healthy
volunteers. Antimicrob Agents Chemother.
2011;55:5507–11.
18. American Thoracic Society. Infectious Diseases
Society of America. Guidelines for the
management of adults with hospital-acquired,
ventilator-associated, and healthcare-associated
pneumonia. Am J Respir Crit Care Med.
2005;171:388–416.
19. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice
guidelines by the infectious diseases Society of
America for the treatment of methicillin-resistant
Staphylococcus aureus infections in adults and
children. Clin Infect Dis. 2011;52:e18–55.
20. Zarjou A, Agarwal A. Sepsis and acute kidney injury.
J Am Soc Nephrol. 2011;22:999–1006.
208 Infect Dis Ther (2013) 2:201–208
123
